New insomnia therapy for children: development of AI for therapy and proof-of-concept trial with Sheffield Children's NHS Foundation Trust

儿童新失眠疗法：与谢菲尔德儿童 NHS 基金会信托基金合作开发人工智能疗法和概念验证试验

• 批准号: 10072037
• 金额: $ 32.27万
• 依托单位: BRAINTRAIN2020 LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10072037
• 关键词: New; insomnia; therapy; children; development

The amount we sleep has been increasingly recognised as having an important impact on our health and well-being. Over recent years we have become increasingly aware of the effects that sleep has on both our physical and mental health. Even one bad night's sleep or late night can affect a person's mood, alertness and memory. The long-term effect of poor sleep can cause a range of life-threatening conditions such as cardiovascular disease, obesity and depression.However, insomnia is a global epidemic affecting up to 25% of children and 35% of adolescents with 43% suffering with insomnia into adulthood (Fernandez-Mendoza, 2022).Our mission is to rid the world of addictive sleeping tablets and provide a good night's sleep for everyone, improving health and well-being.SleepCogni has identified an urgent clinical need for a solution to support children due to the current lack of treatment options. SleepCogni provides an innovative technological solution to this problem. The wearable medical device delivers sleep therapy offering immediate relief when it's needed most. The patented Active-Biofeedback technology delivers personalised therapy and provides unique behavioural insights to make meaningful improvements. This patented technology uses haptic feedback to break the cognitive cycles that prevent sleep. Providing sleep clinicians with an economical and efficient technological solution to manage insomnia.SleepCogni now seek to develop and incorporate AI into our patented Active-Biofeedback therapy to improve the personalisation and engagement. Through our collaborators, Sheffield Children's NHS Foundation Trust, this will then be tested in children under 18 in a proof of concept trial to determine the efficacy and user experience.SleepCogni will act as a first-line therapy solution which will directly address the growing waiting lists, helping paediatric patients self-manage their insomnia alongside their family.

人们越来越认识到我们的睡眠时间对我们的健康和福祉具有重要影响。近年来，我们越来越意识到睡眠对我们的身心健康的影响。即使一晚睡不好或熬夜也会影响一个人的情绪、警觉性和记忆力。睡眠不佳的长期影响会导致一系列危及生命的疾病，如心血管疾病、肥胖和抑郁症。然而，失眠是一种全球流行病，影响高达 25% 的儿童和 35% 的青少年，其中 43% 患有失眠症成年期失眠（Fernandez-Mendoza，2022）。我们的使命是消除世界上成瘾的安眠药，为每个人提供良好的夜间睡眠，改善健康和由于目前缺乏治疗选择，SleepCogni 发现临床迫切需要一种支持儿童的解决方案。 SleepCogni 为这个问题提供了创新的技术解决方案。这款可穿戴医疗设备提供睡眠治疗，可在最需要时立即缓解疼痛。获得专利的主动生物反馈技术提供个性化治疗，并提供独特的行为见解，以做出有意义的改进。这项专利技术利用触觉反馈来打破阻碍睡眠的认知循环。为睡眠临床医生提供经济高效的技术解决方案来管理失眠。SleepCogni 现在寻求开发人工智能并将其纳入我们获得专利的主动生物反馈疗法中，以提高个性化和参与度。然后，通过我们的合作者谢菲尔德儿童 NHS 基金会信托基金，将在概念验证试验中对 18 岁以下儿童进行测试，以确定功效和用户体验。SleepCogni 将作为一线治疗解决方案，直接解决日益增长的等待问题清单，帮助儿科患者与家人一起自我管理失眠。